CHICAGO (Reuters) -The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...

About 2,000 people gathered at the SRC arena for the 2025 Syracuse Heart Walk on Sunday, March 30. The Heart Walk is an ...

Advances in PCI over the past decade mean the procedure can now approximate results only previously achieved with open-heart bypass surgery, new data show.

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery ...

No matter the temperature outside, heated yoga, Pilates or spin classes are drawing in those eager to sweat it out.